0000002025-10-012026-03-310000002026-03-310000002025-03-310000002025-04-012026-03-310000002025-10-012026-03-31in-capmkt:OtherExpenses1Member0000002025-10-012026-03-31in-capmkt:OtherExpenses2Member0000002025-04-012026-03-31in-capmkt:OtherExpenses1Member0000002025-04-012026-03-31in-capmkt:OtherExpenses2Member0000002026-03-31OtherCurrentLiabilitiesDomain10000002026-03-31OtherNoncurrentAssetsDomain10000002025-10-012026-03-31RelatedPartyTransactionDomain10000002025-09-30RelatedPartyTransactionDomain10000002026-03-31RelatedPartyTransactionDomain10000002025-10-012026-03-31RelatedPartyTransactionDomain20000002025-09-30RelatedPartyTransactionDomain20000002026-03-31RelatedPartyTransactionDomain20000002025-10-012026-03-31RelatedPartyTransactionDomain30000002025-09-30RelatedPartyTransactionDomain30000002026-03-31RelatedPartyTransactionDomain30000002025-10-012026-03-31RelatedPartyTransactionDomain40000002025-09-30RelatedPartyTransactionDomain40000002026-03-31RelatedPartyTransactionDomain40000002025-10-012026-03-31RelatedPartyTransactionDomain50000002025-09-30RelatedPartyTransactionDomain50000002026-03-31RelatedPartyTransactionDomain50000002025-10-012026-03-31RelatedPartyTransactionDomain60000002025-09-30RelatedPartyTransactionDomain60000002026-03-31RelatedPartyTransactionDomain60000002025-10-012026-03-31RelatedPartyTransactionDomain70000002025-09-30RelatedPartyTransactionDomain70000002026-03-31RelatedPartyTransactionDomain70000002025-10-012026-03-31RelatedPartyTransactionDomain80000002025-09-30RelatedPartyTransactionDomain80000002026-03-31RelatedPartyTransactionDomain80000002025-10-012026-03-31RelatedPartyTransactionDomain90000002025-09-30RelatedPartyTransactionDomain90000002026-03-31RelatedPartyTransactionDomain90000002025-10-012026-03-31RelatedPartyTransactionDomain100000002025-09-30RelatedPartyTransactionDomain100000002026-03-31RelatedPartyTransactionDomain100000002025-10-012026-03-31RelatedPartyTransactionDomain110000002025-09-30RelatedPartyTransactionDomain110000002026-03-31RelatedPartyTransactionDomain110000002025-10-012026-03-31RelatedPartyTransactionDomain120000002025-09-30RelatedPartyTransactionDomain120000002026-03-31RelatedPartyTransactionDomain120000002025-10-012026-03-31RelatedPartyTransactionDomain130000002025-09-30RelatedPartyTransactionDomain130000002026-03-31RelatedPartyTransactionDomain130000002025-10-012026-03-31RelatedPartyTransactionDomain140000002025-09-30RelatedPartyTransactionDomain140000002026-03-31RelatedPartyTransactionDomain140000002025-10-012026-03-31RelatedPartyTransactionDomain150000002025-09-30RelatedPartyTransactionDomain150000002026-03-31RelatedPartyTransactionDomain150000002025-10-012026-03-31RelatedPartyTransactionDomain160000002025-09-30RelatedPartyTransactionDomain160000002026-03-31RelatedPartyTransactionDomain160000002025-10-012026-03-31RelatedPartyTransactionDomain170000002025-09-30RelatedPartyTransactionDomain170000002026-03-31RelatedPartyTransactionDomain170000002025-10-012026-03-31RelatedPartyTransactionDomain180000002025-09-30RelatedPartyTransactionDomain180000002026-03-31RelatedPartyTransactionDomain180000002025-10-012026-03-31RelatedPartyTransactionDomain190000002025-09-30RelatedPartyTransactionDomain190000002026-03-31RelatedPartyTransactionDomain190000002025-10-012026-03-31RelatedPartyTransactionDomain200000002025-09-30RelatedPartyTransactionDomain200000002026-03-31RelatedPartyTransactionDomain200000002025-10-012026-03-31RelatedPartyTransactionDomain210000002025-09-30RelatedPartyTransactionDomain210000002026-03-31RelatedPartyTransactionDomain210000002025-10-012026-03-31RelatedPartyTransactionDomain220000002025-09-30RelatedPartyTransactionDomain220000002026-03-31RelatedPartyTransactionDomain220000002025-10-012026-03-31AuditorDomain10000002026-03-31Statement10000002025-10-012026-03-31Statement10000002026-03-31Statement20000002025-10-012026-03-31Statement20000002026-03-31StatementDynamic1I1Statement10000002026-03-31StatementDynamic1I2Statement10000002026-03-31StatementDynamic1I3Statement10000002026-03-31StatementDynamic1I4Statement10000002026-03-31StatementDynamic1I5Statement10000002026-03-31StatementDynamic2I1Statement2iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000MEDIORGNOTLISTEDINE0PE401018Medicamen Organics LimitedSMEEquity2025-04-012026-03-312026-05-292026-05-23INRLakhsHalf YearlyYearlySingle segmentPharmaceuticals2026-05-2915:00:002026-05-2917:37:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2026-05-29https://www.medicamenorganics.com/true2falseNo default2025-10-012026-03-31AuditedStandalone45963000150000461130005444700073870000178320003726000475300026886000115031000-689180000-689180000-68918000-6290000-12792000-19082000-49836000000-49836000-4983600012165900010-4.24-4.211. The standalone audited financial results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. <BR> 2. The Company has signed a Memorandum of Understanding (MOU) dated July 15, 2024 and a Share Sale Agreement dated October 08, 2024 with Depot Pharmacy Yego Ltd. (Rwanda, East Africa based company), having its corporate office at Plot No. B1, Kigali City Market, Nyarugenge, Kigali-20093, Rwanda, East Africa. The Company has invested in a 51% stake in Depot Pharmacy Yego Ltd. While the transaction agreement was executed on October 08, 2024, the actual acquisition was completed on January 16, 2025, which is considered as the acquisition date. <BR> Further, the Company incorporated a subsidiary namely Grande Etoile Pharmaceuticals Limited on December 27, 2024, in which the Company holds 50.92% shareholding. <BR> 3. The Statutory Auditors of the Company have audited the above results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> 4. There were no investor complaints pending at the beginning or at the end of the half-year ended March 31, 2026. <BR> 5. The financial results are also available on the websites of the Company at www.medicamenorganics.com and NSE at www.nseindia.com. <BR> 6. The above standalone audited financial results for the half-year and year ended March 31, 2026 were reviewed and recommended by the Audit Committee and subsequently approved and taken on record by the Board of Directors at their respective meetings held on May 29, 2026. The results have been audited by the Statutory Auditors of the Company. <BR> 7. The Company has received intimation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006. Necessary disclosures relating to outstanding dues as at the year end have been made. The Company has also provided for interest on outstanding dues payable to MSME suppliers as on March 31, 2026. <BR> 8. The results for the half-year and year ended March 31, 2026 have been audited by the Statutory Auditors in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015. <BR> 9. These financial results have been prepared in accordance with the recognition and measurement principles laid down under Accounting Standards ("AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other generally accepted accounting principles in India. <BR> 10. Earnings Per Share (EPS) has been computed in accordance with Accounting Standard (AS) 20 on Earnings Per Share. EPS for the half-years ended March 31, 2026, September 30, 2025 and March 31, 2025 have not been annualised. The weighted average number of equity shares outstanding during the respective periods has been considered for computing Basic and Diluted EPS. <BR> 11. Comparative figures for the half-year and year ended March 31, 2026 have been audited by the Statutory Auditors of the Company. <BR> 12. The figures for the half-year ended March 31, 2026 represent the balancing figures between the audited figures for the full financial year ended March 31, 2026 and the unaudited figures for the half-year ended September 30, 2025. <BR> 13. The Company issued 31,00,000 equity shares of face value 10 each at a premium of 24 per share through an Initial Public Offer (IPO) and was listed on the NSE Emerge Platform on June 28, 2024. <BR> . Contingent Liabilities and Pending Litigations <BR> 14A. Contingent Liabilities ( in Lakhs) <BR> Particulars Next Date of Hearing As at 31.03.2026 As at 31.03.2025 <BR> Case against the Company filed by Prakash Parcel Services Ltd. 20.08.2026 2.34 2.34 <BR> Case against the Company filed by Multani Pharmaceuticals 29.05.2026 7.18 Nil <BR> Margin Money (FDR) for Bank Guarantee on behalf of third party (Margin FDR of 56,200) - 5.62 6.42 <BR> 14B. Statutory Dues under Dispute <BR> Statute Nature of Dues Amount ( in Lakhs) Financial Year Description Forum <BR> Income Tax Department Income Tax 13.27 AY 2017-18 Assessment Year Commissioner of Income Tax (Appeals) <BR> GST Difference in Output Tax Liability & ITC Claimed 17.74 FY 2022-23 Reply to be filed Deputy Commissioner (Assessment)-2, Haridwar <BR> <BR> 14C. Pending Litigations <BR> Party Name Nature Amount ( in Lakhs) Next Hearing Description Forum <BR> Europa Biocare Pvt. Ltd. Civil Case 7.23 29.07.2026 Recovery suit filed by Company Rohini Court <BR> Wafture Healthcare Pvt. Ltd. Civil Case 5.70 19.09.2026 Recovery suit filed by Company Rohini Court <BR> Paseca Health Care Civil Case 5.53 29.07.2026 Recovery suit filed by Company Rohini Court <BR> Ujjwal Overseas Civil Case 17.17 29.07.2026 Recovery suit filed by Company Rohini Court <BR> Mex Life Care Ltd. Civil Case (NI Act) 13.72 01.08.2026 Recovery suit filed by Company Rohini Court <BR> 15. During FY 2024-25, the Company undertook an IPO of 31,00,000 equity shares of face value 10 each at an issue price of 34 per share (including premium of 24 per share), aggregating 1,054.00 lakhs. The shares were allotted on June 26, 2024 and listed on NSE Emerge on June 28, 2024. <BR> 16. The Company has written off 33.09 lakhs being GST refund receivable which is no longer recoverable from the GST Department. <BR> 17. The GST Department, Uttarakhand is conducting scrutiny of the Company's GST returns for FY 2024-25. During the year, the Company voluntarily paid 50.00 lakhs through Form GST DRC-03. Management believes that no further material liability is likely to arise and accordingly no additional provision has been recognised. <BR> 18. During FY 2025-26, the Company issued 4,65,910 warrants convertible into equivalent number of equity shares of face value 10 each at an issue price of 64.39 per warrant, in accordance with SEBI ICDR Regulations, 2018. <BR> 19. Pursuant to Special Resolution dated January 24, 2026, 4,65,910 warrants were converted into fully paid-up equity shares and allotted to Mr. Bal Kishan Gupta at an issue price of 64.39 per share. <BR> 20. Sundry creditors include advance received of 40.21 lakhs from Escorts Pharmaceuticals Rwanda Limited (EPRL) in March 2025. No supplies were executed against this advance up to March 31, 2026 due to geopolitical tensions and logistical disruptions in the East African region, including Rwanda-DRC border instability. The matter is under continuous review and the Company is coordinating with the customer and logistics partners. <BR> 21. Balances of certain debtors and creditors are subject to confirmation and reconciliation. <BR> 22. Based on management assessment, the recoverable value of assets exceeds their carrying amount and therefore no impairment provision is required. <BR> 23. Previous year/period figures have been regrouped and reclassified wherever necessary to conform to current year classifications. <BR> 24. Since the Company operates in a single business segment, the disclosure requirements under AS-17 Segment Reporting are not applicable. <BR> 2025-04-012026-03-31AuditedStandalone216480000724000217204000156488000-39030000363800007058000887300055352000260248000-430440000-430440000-430440000-12590000-12590000-30454000000-30454000-30454000121659000100-2.58-2.58Direct Expenses11730000Other Expenses15156000Direct Expenses27278000Other Expenses280740001216590001663970002880560000104500002477000129270001264410001242700041632000540590002281300059900020391200050489500012832000044940009210001337350002709000991000011948000149383000010295000017972800059650000668690003555120005048950001. The standalone audited financial results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. <BR> 2. The Company has signed a Memorandum of Understanding (MOU) dated July 15, 2024 and a Share Sale Agreement dated October 08, 2024 with Depot Pharmacy Yego Ltd. (Rwanda, East Africa based company), having its corporate office at Plot No. B1, Kigali City Market, Nyarugenge, Kigali-20093, Rwanda, East Africa. The Company has invested in a 51% stake in Depot Pharmacy Yego Ltd. While the transaction agreement was executed on October 08, 2024, the actual acquisition was completed on January 16, 2025, which is considered as the acquisition date. <BR> Further, the Company incorporated a subsidiary namely Grande Etoile Pharmaceuticals Limited on December 27, 2024, in which the Company holds 50.92% shareholding. <BR> 3. The Statutory Auditors of the Company have audited the above results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. other current liabilities22813000other non-current assets1194800006196000000000006196000-28056000677930002171000-629170009532000-10971000-22448000-16252000-592960000-7058000-223000124700012197000-4151100000-41511000090000000000164660000000000223000000-1625200000-162520004659000-7500000015595000007058000025341000310370000031037000-267260000-26726000326910005965000Medicamen Organics Limited******Grande Etoile Pharmaceuticals Limited******The company has formed subsidiary with 50.96% shareholdingInvestmentNo Remarks025460002546000Medicamen Organics Limited******Grande Etoile Pharmaceuticals Limited******The company has formed subsidiary with 50.96% shareholdingLoanNo Remarks504600005046000Medicamen Organics Limited******Grande Etoile Pharmaceuticals Limited******The company has formed subsidiary with 50.96% shareholdingAny other transactionReimbursement of expensesNo Remarks03100031000Medicamen Organics Limited******Depot Yego Pharmacy Limited******The compoany has acquired 51% shareholding in the companyInvestmentNo Remarks0163000163000Medicamen Organics Limited******Redline Healthcare Private Limited******Associate ConcernLoanNo Remarks8910001069000280000Medicamen Organics Limited******Redline Healthcare Private Limited******Director is a parterLoanNo Remarks0380000380000Medicamen Organics Limited******Bal Kishan Gupta******DirectorRemunerationNo Remarks1752000162000565000Medicamen Organics Limited******Bal Kishan Gupta******DirectorLoanNo Remarks146850007121800056533000Medicamen Organics Limited******Ritu Gupta******Director's SpouseRemunerationNo Remarks73900080000280000Medicamen Organics Limited******Ashutosh Gupta******DirectorRemunerationNo Remarks2778000184000524000Medicamen Organics Limited******Ashutosh Gupta******DirectorLoanNo Remarks1120000112000Medicamen Organics Limited******Shivani Chopra******ShareholderRemunerationNo Remarks1841000121000207000Medicamen Organics Limited******BKG and Sons HUF******Director's HUFLoanNo Remarks000Medicamen Organics Limited******Brijesh Kumar Chaubey******DirectorRemunerationNo Remarks1604000136000162000Medicamen Organics Limited******Jasbal Pharma LLP******LLP in which director is PartnerSale of goods or servicesNo Remarks57100075000346000Medicamen Organics Limited******Loire Cosmetics Limited******Grande Etoile Pharmaceuticals Limited SubsidiaryInvestmentNo Remarks2540000254000Medicamen Organics Limited******Sneh Gaur******Non Executive DirectorAny other transactionSitting feesNo Remarks50000225000170000Medicamen Organics Limited******Rajinder Kumar Gupta******Independent DirectorAny other transactionSitting feesNo Remarks700004500078000Medicamen Organics Limited******Sachin Gupta******Independent DirectorAny other transactionSitting feesNo Remarks750004500083000Medicamen Organics Limited******Rakesh Kumar******Independent DirectorAny other transactionSitting feesNo Remarks300004500042000Medicamen Organics Limited******Lalit Gupta******Chief Financial OfficerAny other transactionSalaryNo Remarks124000065000125000Medicamen Organics Limited******Varsha Bansal******Company SecretaryAny other transactionSalary including PFNo Remarks180000130001300031918000AuditedtrueN C RAJ & ASSOCIATEStrue2026-02-28Public Issues2024-06-261054000002026-03-31falsetruetrue2026-01-27Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectusFunding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.No comments from the auditorBal Kishan GuptaManaging DirectorNew Delhi2026-05-29Preferential Issues2025-03-13299990002026-03-31falsefalsefalsefalsefalseFunding of expenses proposed to be incurred towards Product registration in the international markets;Yes300000001624400013756000162440001. The Company came up with the public issue of 31,00,000 equity shares of Face value of Rs.10/- each <br></br> ("equity shares") with the price band of Rs.32 to 34 through Book Building Method, IPO was open for <br></br> subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 <br></br> equity shares of Face value of 10/- each ("equity shares") for cash at a price of Rs. 34/- per equity share <br></br> (including a share premium of Rs. 24 per equity share) aggregating to Rs. 10,54,00,000 on Wednesday, June <br></br> 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of <br></br> India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure <br></br> Requirements) Regulations, 2018, as amended. <br></br> 2. Cumulative fund utilized as on March 31st 2026 is Rs. 1054,00,000 <br></br> 3. Funding of expenses proposed to be incurred towards Product registration in the international markets ot <br></br> Rs.300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains <br></br> unutilized as 30th September 2025 (the Unutilized Amount), however, the Company no longer requires these <br></br> funds for such purpose, on February 26, 2026, Special resolution passed to consider and approve variation in <br></br> the objects of the issue relating to initial public offering (ipo) for which amount was raised through prospectus. <br></br> <br></br> The unutilized IPO proceeds of Rs. 162.44 (In lakhs) i.e. 15.41% of IPO proceeds, is intended to be utilized <br></br> towards the following purposes. <br></br> S.No. 1 <br></br> Object of the Issue as per DRHP - expenses proposed to be incurred towards Product registration in the international markets <br></br> Utilisation Planned as per prospectus - 300 <br></br> Amount actually Utilised by the company - 137.56 <br></br> Balance available for Utilisation - 162.44 <br></br> Revised Object as per Special resolution - To meet out the working capital requirements of our company <br></br> Amount to be funded from the IPO Proceeds - 162.44Plant updation and increase in production capacityNo225000000225000000Funding working capital requirements of our CompanyNo400000000562440000General corporate purposeNo3900000039000000Issue Related ExpensesNo9000000090000000Working capital requirements and General corporate purposeNo299990000299990000As on March 31, 2026, funds received against the warrants subscription money on 4,65,910 warrants amounted to Rs. 2,99,99,945,. The Company has spent total funds towards the objects disclosed in the offer document/Postal Ballot Notice. <br></br> 1. During the financial year ended March 31, 2026, the Company came up with the preferential issue of 4,65,910 warrants convertible into equivalent number of fully paid-up equity shares of face value of ? 10/- (Rupee Ten Only) each ("Equity Shares") at the option of Allottees, in one or more tranches, within 18 (eighteen) months from the date of allotment at issue price of Rs. 64.39/-. <br></br> The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, <br></br> 2018, as amended. <br></br> 2. Cumulative fund utilized as on March 31, 2026 is Rs. 299.99